Sotera Health Company (Nasdaq: SHC) announced a secondary offering of 25 million shares of its common stock on March 4 2026. The shares are being sold by affiliates of Warburg Pincus and GTCR; the company will not receive any proceeds from the transaction. Wells Fargo Securities is underwriting the offering, which will be made available on Nasdaq, the over‑the‑counter market, or through negotiated transactions at market or negotiated prices. Sotera Health will cover the offering expenses under its amended registration rights agreement.
The sale is a typical private‑equity exit following the company’s 2020 IPO. Because it is a secondary sale, the transaction does not dilute existing shareholders or alter the company’s capital structure. The offering is not a primary issuance of new shares, so Sotera Health’s balance sheet and cash position remain unchanged.
Sotera Health’s 2025 financial results provide context for the offering. The company reported net revenues of $1.164 billion, a 5.7% year‑over‑year increase, and Adjusted EBITDA of $593.8 million, giving an adjusted margin of 51.0%. Management guided 2026 revenue to $1.233 billion–$1.251 billion, implying 5%–6.5% constant‑currency growth. These figures underscore a steady expansion and a strong operating foundation.
Michael Petras, Chairman and CEO, said, “We are pleased with our strong financial performance in 2025, which reflects our commitment to operational excellence and strategic growth initiatives. Our investments in new technologies and facilities position us well for continued success.” He added, “This morning, we announced another strong year of performance, extending our track record of year‑over‑year revenue growth to 20 consecutive years.”
Investors reacted negatively to the announcement, largely because the secondary sale increases the supply of Sotera Health shares in the market. The company’s financials, however, remain unchanged, and the transaction reflects the typical exit strategy of its private‑equity owners.
Sotera Health operates through its Sterigenics, Nordion, and Nelson Labs brands, providing sterilization and laboratory testing services to the healthcare sector. The company has faced litigation related to emissions from its facilities but has continued to grow, supported by a history of 20 consecutive years of revenue growth and a robust 51% adjusted EBITDA margin. The private‑equation exit aligns with the firm’s investment cycle and does not signal any operational or strategic shift for Sotera Health.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.